Boehringer Ingelheim Buys ViraTherapeutics

Boehringer Ingelheim Buys ViraTherapeutics
Boehringer Ingelheim Buys ViraTherapeutics

Boehringer Ingelheim has taken an option to buy all the shares of ViraTherapeutics, an Austrian biopharma that specializes in developing immunotherapy drugs based on oncolytic viruses.

The total transaction value of €210 million is based on an option and share purchase agreement that the two companies signed in August 2016.

ViraTherapeutics’ lead candidate is VSV-GP (Vesicular Stomatitis Virus (VSV) with modified glycoprotein (GP), which is being investigated alone and in combination with other therapies. VSV-GP has shown promising results in preclinical models, especially in combination with key immune modulatory principles that Boehringer is developing.

“The acquisition of ViraTherapeutics with its exciting oncolytic virus platform is the conclusion of a trusting and close cooperation over two years,” said Heinz Schwer, CEO of ViraTherapeutics. “We are highly optimistic that our VSV-based development programs and technology will complement Boehringer Ingelheim’s immuno-oncology franchise and will serve as a source of innovative, new treatment options for patients living with cancer.”

Oncolytic viral therapy has two modes of action. First, the virus specifically replicates in and kills cancer cells. Second, viral infection stimulates the immune system to recognize and kill the cancer cells, further enhancing tumor control.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.